|
See related Exforge information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Per 5/80 mg tab Amlodipine besylate 5 mg, valsartan 80 mg. Per 5/160 mg tab Amlodipine besylate 5 mg, valsartan 160 mg. Per 10/160 mg tab Amlodipine besylate 10 mg, valsartan 160 mg |
|
Indications |
Treatment of HTN.
Click to view Exforge detailed prescribing infomation |
|
Dosage |
1 tab daily.
Click to view Exforge detailed prescribing infomation |
|
Overdosage |
View Exforge overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Severe hepatic impairment, biliary cirrhosis or cholestasis. Severe renal impairment (GFR <30 mL/min/1.73 m2) & dialysis patients. Pregnancy.
Click to view Exforge detailed prescribing infomation |
|
Special Precautions |
Na- &/or vol-depleted patients. Concomitant use w/ K supplements, K-sparing diuretics, salt substitutes containing K or other drugs that may increase K levels (eg heparin). Monitor K levels regularly. Mild to moderate hepatic impairment or biliary obstructive disorders. Primary hyperaldosteronism. Severe heart failure, aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy. May affect ability to drive or operate machinery. Lactation. Elderly >65 yr. Childn <18 yr.
Click to view Exforge detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, nasopharyngitis, influenza, oedema, pitting oedema, facial oedema, peripheral oedema, fatigue, flushing, asthenia, hot flushes.
View ADR Monitoring Form |
|
Drug Interactions |
Amlodipine CYP3A4 inhibitors & inducers (anticonvulsants, rifampicin, H. perforatum). Valsartan Lithium; K-sparing diuretics, K supplements, salt substitutes containing K & other drugs that may increase K levels; NSAIDs. Amlodipine + Valsartan α-blockers, diuretics, TCAs.
View more drug interactions with Exforge |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Exforge storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Exforge description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Exforge mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
